An exploratory analysis of the TROPION-Lung01 phase 3 trial revealed TROP2 expression, measured using AstraZeneca’s computational pathology platform, as a predictor of clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with datopotamab deruxtecan (Dato-DXd).
In patients whose tumors showed high TROP2-QCS biomarker levels, Dato-DXd significantly improved efficacy compared to docetaxel. A greater proportion of patients with nonsquamous NSCLC had TROP2-QCS positive tumors than those with squamous NSCLC.
In the TROP2-QCS biomarker-positive group, Dato-DXd reduced the risk of disease progression or death by 43% compared to docetaxel. Notably, this improvement in efficacy was more pronounced in the subgroup of patients with nonsquamous NSCLC without actionable genomic alterations, where Dato-DXd reduced the risk by 48%.
These findings suggest that the TROP2-QCS biomarker has the potential to identify patients who are likely to benefit most from Dato-DXd therapy in advanced NSCLC. Further research is needed to validate this biomarker and determine its role in guiding treatment decisions.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.